Vaxcyte Announces the Completion of a $575 Million Public Offering, Including…
SAN CARLOS, Calif., April 21, 2023 (GLOBE NEWSWIRE) — Vaxcyte, Inc. PCVX, an innovative, clinical-stage vaccines company developing high-fidelity vaccines to protect humanity from the